SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix

Core Insights - OncoHelix is the first laboratory in Canada to implement MSK-ACCESS® powered with SOPHiA DDM™, enhancing its oncology testing capabilities through advanced liquid biopsy solutions [1][4] - The partnership with SOPHiA GENETICS aims to leverage cutting-edge technology for rapid validation of genomic panels and sequencing, supporting OncoHelix's mission in precision oncology [3][4] Company Overview - OncoHelix, based in Calgary, Canada, specializes in genomic and molecular testing services globally and collaborates with the Hematology Translational Lab at the University of Calgary [2] - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine, providing the SOPHiA DDM™ platform for analyzing complex genomic data [6] Technology and Innovation - The MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized ctDNA assay developed by Memorial Sloan Kettering Cancer Center, analyzing 146 key cancer-associated genes [4] - Liquid biopsy testing offers a less invasive alternative to traditional solid tumor biopsies, extracting cell-free DNA from blood plasma to reveal circulating tumor DNA [3]